Transcranial Magnetic Treatment (TMS) in Unipolar Depression
Primary Purpose
Unipolar Depression
Status
Completed
Phase
Early Phase 1
Locations
Canada
Study Type
Interventional
Intervention
Transcranial Magnetic Stimulation (TMS)
Sponsored by

About this trial
This is an interventional treatment trial for Unipolar Depression focused on measuring Repetitive Transcranial Magnetic Stimulation, TMS
Eligibility Criteria
Inclusion Criteria: Major Depression No physical health problems Exclusion Criteria: History of Epilepsy Metal in the head/neck or skull Pacemaker Pregnancy
Sites / Locations
- St.Joseph's Healthcare, rTMS Laboratory, Mood Disorders Program, 100 West Fifth Street
Outcomes
Primary Outcome Measures
Hamilton Depression Rating Scale
Beck Depression Rating Scale
Secondary Outcome Measures
Quantitive Electroencephalographic(QEEG)activity and measures of regional cerebral blood flow
Full Information
NCT ID
NCT00186784
First Posted
September 13, 2005
Last Updated
August 2, 2011
Sponsor
St. Joseph's Healthcare Hamilton
Collaborators
Queen's University, Kingston, Ontario
1. Study Identification
Unique Protocol Identification Number
NCT00186784
Brief Title
Transcranial Magnetic Treatment (TMS) in Unipolar Depression
Official Title
Repetitive Transcranial Magnetic Stimulation (rTMS) in Unipolar Depression
Study Type
Interventional
2. Study Status
Record Verification Date
August 2011
Overall Recruitment Status
Completed
Study Start Date
December 2000 (undefined)
Primary Completion Date
July 2011 (Actual)
Study Completion Date
July 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
St. Joseph's Healthcare Hamilton
Collaborators
Queen's University, Kingston, Ontario
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Repetitive Transcranial Magnetic Stimulation (rTMS) can improve mood and decrease sadness in patients with depression.
In this study, the investigators seek to increase their understanding about how rTMS improves depression, and to determine which form of rTMS is most effective for depression, when used in combination with antidepressant medication.
Detailed Description
Patients will be assigned for 4 treatment arms, receiving either left high frequency plus right low frequency, or left high frequency plus right sham, or left sham, plus right low frequency, or left sham plus right sham treatment. All subjects will receive treatments for 10 days and will be followed for another 4 weeks.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Unipolar Depression
Keywords
Repetitive Transcranial Magnetic Stimulation, TMS
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
Transcranial Magnetic Stimulation (TMS)
Intervention Description
treatment for 10 days
Primary Outcome Measure Information:
Title
Hamilton Depression Rating Scale
Time Frame
Pre TMS and post TMS
Title
Beck Depression Rating Scale
Time Frame
pre TMS and post TMS
Secondary Outcome Measure Information:
Title
Quantitive Electroencephalographic(QEEG)activity and measures of regional cerebral blood flow
Time Frame
pre TMS and post TMS as well as post phase II, second set of TMS
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Major Depression
No physical health problems
Exclusion Criteria:
History of Epilepsy
Metal in the head/neck or skull
Pacemaker
Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gary Hasey, MD
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
St.Joseph's Healthcare, rTMS Laboratory, Mood Disorders Program, 100 West Fifth Street
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 3K7
Country
Canada
12. IPD Sharing Statement
Citations:
PubMed Identifier
35086123
Citation
Jacquot F, Khoury S, Labrum B, Delanoe K, Pidoux L, Barbier J, Delay L, Bayle A, Aissouni Y, Barriere DA, Kultima K, Freyhult E, Hugo A, Kosek E, Ahmed AS, Jurczak A, Lingueglia E, Svensson CI, Breuil V, Ferreira T, Marchand F, Deval E. Lysophosphatidylcholine 16:0 mediates chronic joint pain associated to rheumatic diseases through acid-sensing ion channel 3. Pain. 2022 Oct 1;163(10):1999-2013. doi: 10.1097/j.pain.0000000000002596. Epub 2022 Jan 27.
Results Reference
derived
Learn more about this trial
Transcranial Magnetic Treatment (TMS) in Unipolar Depression
We'll reach out to this number within 24 hrs